Instadose Pharma

INSD

Drug Manufacturers - Specialty & Generic · Healthcare

Price

$0.00

+0.00 (+0.00%)

Market Cap

$53,193

Winston Score

–

No score yet — Winston is napping.

We couldn’t gather enough financial data to score this stock reliably.

Instadose Pharma Corp. is a small pharmaceutical company focused on developing drug delivery technology and cannabis-based medicines. Its core idea is a patented ingestible sensor capsule that can track when a patient takes their medication and send that data to a smartphone or doctor. The target customers are patients, healthcare providers, and potentially pharmaceutical partners who want better tools to make sure people actually take their medicine as prescribed.

The company earns revenue through licensing its drug delivery technology and developing pharmaceutical products, though it remains in an early stage with minimal commercial sales. It operates primarily in North America and is a micro-cap company with a very small market presence. The financial data showing zero gross margin and zero operating margin reflects that it is not yet generating meaningful revenue. The biggest risk is that the company has not proven it can scale commercially, and early-stage pharmaceutical companies frequently run out of cash before reaching profitability.

Winston Score History

Growth Profile

For growth stock investors

When traditional metrics don't capture the full picture, these are the signals growth stock investors use instead.

Revenue Growth

Revenue data limited

EPS Growth

<−1,000% YoY

YoY Growth Rate

Earnings declining

R&D Spend

$0/ year

Research and development spending

Insider Activity

24.4%ownership

→ Flat

Insiders holding steady — not selling despite ability to

Cash Position

Cash flow positive

$5,328 cash & investments

Company generates more cash than it spends — no dilution risk from fundraising

The Winston Score above measures business quality today. Growth stocks often score lower because they invest in the future rather than maximising current profits. These metrics show what matters most for evaluating that future.

Share count broadly stable

0.0% over 4y

The share count has stayed roughly flat over this period — little dilution or buyback activity.

Diluted shares outstanding: 75.0M (2017) → 75.0M (2021)

Score breakdown

Every number that matters to educated investors.

Each metric is explained in plain language so you know exactly what you're looking at. Start your free trial now.

Quality

Gross Margin

N/A

—

Data not available

Operating Margin

N/A

—

Data not available

ROCE

-3.2%

Weak — -3.2% return on capital

Negative ROIC means the business is losing money on every dollar invested in it.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Growth

Sales YoY

N/A

—

Data not available

EPS YoY

N/A

—

Data not available

EPS Consistency

0/8 quarters

Earnings rarely grow — volatile business

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Cash Flow

Cash Conversion

N/A

—

Data not available

FCF Margin

N/A

—

Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Stability

Debt / Equity

0.00

Conservative — low debt load (0.00)

Interest Cover

N/A

Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Valuation

P/E Ratio (TTM)

N/M

—

Negative earnings — P/E not meaningful

P/E vs Forward

N/A

not available

Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Dividends

Not applicable for this business.

🔒 See full fundamentals and if they are improving or declining — click here for your free trial now.

Start free trial